» Articles » PMID: 21430056

Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the in Vivo Development of Neutralizing Antibodies

Abstract

A major goal of human immunodeficiency virus type 1 (HIV-1) vaccine efforts is the design of Envelope (Env)-based immunogens effective at eliciting heterologous or broad neutralizing antibodies (NAbs). We hypothesized that programming the B-cell response could be achieved by sequentially exposing the host to a collection of env variants representing the viral quasispecies members isolated from an individual that developed broad NAbs over time. This ordered vaccine approach (sequential) was compared to exposure to a cocktail of env clones (mixture) and to a single env variant (clonal). The three strategies induced comparable levels of the autologous and heterologous neutralization of tier 1 pseudoviruses. Sequential and mixture exposure to quasispecies led to epitope targeting similar to that observed in the simian-human immunodeficiency virus (SHIV)-infected animal from which the env variants were cloned, while clonal and sequential exposure led to greater antibody maturation than the mixture. Therefore, the sequential vaccine approach best replicated the features of the NAb response observed in that animal. This study is the first to explore the use of a collection of HIV-1 env quasispecies variants as immunogens and to present evidence that it is possible to educate the B-cell response by sequential exposure to native HIV-1 quasispecies env variants derived from an individual with a broadened NAb response.

Citing Articles

The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.

Kutzler M, Cusimano G, Joyner D, Konopka E, Muir R, Barnette P Res Sq. 2024; .

PMID: 38746176 PMC: 11092827. DOI: 10.21203/rs.3.rs-4139764/v1.


Enhancement of Neutralization Responses through Sequential Immunization of Stable Env Trimers Based on Consensus Sequences from Select Time Points by Mimicking Natural Infection.

Wan M, Yang X, Sun J, Giorgi E, Ding X, Zhou Y Int J Mol Sci. 2023; 24(16).

PMID: 37628824 PMC: 10454455. DOI: 10.3390/ijms241612642.


Steering and controlling evolution - from bioengineering to fighting pathogens.

Lassig M, Mustonen V, Nourmohammad A Nat Rev Genet. 2023; 24(12):851-867.

PMID: 37400577 PMC: 11137064. DOI: 10.1038/s41576-023-00623-8.


Moving the needle: Employing deep reinforcement learning to push the boundaries of coarse-grained vaccine models.

Faris J, Orbidan D, Wells C, Petersen B, Sprenger K Front Immunol. 2022; 13:1029167.

PMID: 36405722 PMC: 9670804. DOI: 10.3389/fimmu.2022.1029167.


Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV.

Conti S, Ovchinnikov V, Faris J, Chakraborty A, Karplus M, Sprenger K PLoS Comput Biol. 2022; 18(4):e1009391.

PMID: 35442968 PMC: 9020693. DOI: 10.1371/journal.pcbi.1009391.


References
1.
Vaine M, Wang S, Hackett A, Arthos J, Lu S . Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010; 28(17):2999-3007. PMC: 2847033. DOI: 10.1016/j.vaccine.2010.02.006. View

2.
Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B . Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005; 79(10):6528-31. PMC: 1091724. DOI: 10.1128/JVI.79.10.6528-6531.2005. View

3.
Scheid J, Mouquet H, Feldhahn N, Seaman M, Velinzon K, Pietzsch J . Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458(7238):636-40. DOI: 10.1038/nature07930. View

4.
Anderson D, Carlos M, Nguyen L, Torres J . Overcoming original (antigenic) sin. Clin Immunol. 2001; 101(2):152-7. DOI: 10.1006/clim.2001.5114. View

5.
Blish C, Sather D, Sellhorn G, Stamatatos L, Sun Y, Srivastava I . Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol. 2009; 84(5):2573-84. PMC: 2820908. DOI: 10.1128/JVI.01687-09. View